JPS6228124B2 - - Google Patents
Info
- Publication number
- JPS6228124B2 JPS6228124B2 JP52005978A JP597877A JPS6228124B2 JP S6228124 B2 JPS6228124 B2 JP S6228124B2 JP 52005978 A JP52005978 A JP 52005978A JP 597877 A JP597877 A JP 597877A JP S6228124 B2 JPS6228124 B2 JP S6228124B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- particles
- weight
- medicament
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 127
- 239000008188 pellet Substances 0.000 claims description 112
- 229940079593 drug Drugs 0.000 claims description 94
- 239000002245 particle Substances 0.000 claims description 93
- 239000008187 granular material Substances 0.000 claims description 84
- 239000000843 powder Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 239000002775 capsule Substances 0.000 claims description 30
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 27
- 230000009467 reduction Effects 0.000 claims description 22
- 229960000265 cromoglicic acid Drugs 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 14
- 239000011148 porous material Substances 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 9
- 239000002002 slurry Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000001125 extrusion Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000009736 wetting Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000011221 initial treatment Methods 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- 238000005243 fluidization Methods 0.000 claims 1
- 229960001317 isoprenaline Drugs 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000003186 pharmaceutical solution Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000005054 agglomeration Methods 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000010419 fine particle Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- -1 For example Substances 0.000 description 1
- HQARDVLSJLCFBA-UHFFFAOYSA-N 4-[(4-aminophenyl)carbamoyl]-1h-imidazole-5-carboxylic acid Chemical compound C1=CC(N)=CC=C1NC(=O)C1=C(C(O)=O)NC=N1 HQARDVLSJLCFBA-UHFFFAOYSA-N 0.000 description 1
- AHOWSDUPGJRPTJ-UHFFFAOYSA-N 5-[1-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid Chemical class O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OC(C(O)C)OC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 AHOWSDUPGJRPTJ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VQKLDJLGLNXQAN-UHFFFAOYSA-L [Na+].[Na+].C1=CC=C2OC(C(=O)[O-])=CC(=O)C2=C1.C1=CC=C2OC(C(=O)[O-])=CC(=O)C2=C1 Chemical compound [Na+].[Na+].C1=CC=C2OC(C(=O)[O-])=CC(=O)C2=C1.C1=CC=C2OC(C(=O)[O-])=CC(=O)C2=C1 VQKLDJLGLNXQAN-UHFFFAOYSA-L 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000012438 extruded product Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19743486A JPS62246571A (ja) | 1976-01-23 | 1986-08-25 | 二ナトリウムクロモグリケ−ト |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB260876 | 1976-01-23 | ||
| GB260676A GB1569611A (en) | 1976-01-23 | 1976-01-23 | Pelletised or granular medicament formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5294413A JPS5294413A (en) | 1977-08-09 |
| JPS6228124B2 true JPS6228124B2 (no) | 1987-06-18 |
Family
ID=26237614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP597877A Granted JPS5294413A (en) | 1976-01-23 | 1977-01-24 | Soft pellet or granular medicine |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS5294413A (no) |
| AU (1) | AU506878B2 (no) |
| CA (1) | CA1116516A (no) |
| DK (1) | DK27177A (no) |
| ES (1) | ES455273A1 (no) |
| FI (1) | FI67663C (no) |
| FR (1) | FR2361104A2 (no) |
| IE (1) | IE45260B1 (no) |
| LU (1) | LU76618A1 (no) |
| NO (1) | NO148542C (no) |
| SE (1) | SE442950B (no) |
| ZA (1) | ZA77327B (no) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3268533D1 (en) * | 1981-07-24 | 1986-02-27 | Fisons Plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
| US6102036A (en) * | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
-
1977
- 1977-01-05 IE IE14/77A patent/IE45260B1/en not_active IP Right Cessation
- 1977-01-11 FI FI770070A patent/FI67663C/fi not_active IP Right Cessation
- 1977-01-20 FR FR7701501A patent/FR2361104A2/fr active Granted
- 1977-01-20 ZA ZA770327A patent/ZA77327B/xx unknown
- 1977-01-21 CA CA000270236A patent/CA1116516A/en not_active Expired
- 1977-01-21 NO NO770198A patent/NO148542C/no unknown
- 1977-01-21 LU LU76618A patent/LU76618A1/xx unknown
- 1977-01-21 DK DK27177A patent/DK27177A/da not_active Application Discontinuation
- 1977-01-21 SE SE7700665A patent/SE442950B/xx not_active IP Right Cessation
- 1977-01-22 ES ES455273A patent/ES455273A1/es not_active Expired
- 1977-01-24 JP JP597877A patent/JPS5294413A/ja active Granted
- 1977-01-24 AU AU21589/77A patent/AU506878B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2158977A (en) | 1978-08-03 |
| FI67663C (fi) | 1985-05-10 |
| IE45260B1 (en) | 1982-07-28 |
| NO770198L (no) | 1977-07-26 |
| FR2361104B2 (no) | 1982-09-17 |
| FR2361104A2 (fr) | 1978-03-10 |
| NO148542C (no) | 1983-11-02 |
| DK27177A (da) | 1977-07-24 |
| SE442950B (sv) | 1986-02-10 |
| AU506878B2 (en) | 1980-01-24 |
| LU76618A1 (no) | 1977-08-12 |
| SE7700665L (sv) | 1977-07-24 |
| CA1116516A (en) | 1982-01-19 |
| JPS5294413A (en) | 1977-08-09 |
| FI67663B (fi) | 1985-01-31 |
| NO148542B (no) | 1983-07-25 |
| ES455273A1 (es) | 1978-04-01 |
| IE45260L (en) | 1977-07-23 |
| FI770070A (no) | 1977-07-24 |
| ZA77327B (en) | 1977-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4161516A (en) | Composition for treating airway disease | |
| JPS5910326B2 (ja) | 軟質ペレツト状薬物の製造方法 | |
| US4590206A (en) | Inhalation pharmaceuticals | |
| US5260306A (en) | Inhalation pharmaceuticals | |
| JP3011770B2 (ja) | 吸入適用のための製剤 | |
| PL204733B1 (pl) | Sposób wytwarzania proszków do inhalacji | |
| JP4610189B2 (ja) | 粉末組成物を製造するためのスプリンクリング方法 | |
| WO1999027911A1 (fr) | Medicament en pastilles souples et procede de fabrication | |
| GB2105189A (en) | Inhalation drugs | |
| JP4610190B2 (ja) | 吸入可能な粉末の製造方法 | |
| GB1569611A (en) | Pelletised or granular medicament formulation | |
| JPS6228124B2 (no) | ||
| DK2094240T3 (en) | Stable powder formulation containing an anticholinergic | |
| JP5799061B2 (ja) | トスフロキサシンおよびポリビニルピロリドンを含有する粒状固形製剤 | |
| JPH0142950B2 (no) | ||
| CA2670153A1 (en) | Stable powder formulation containing a novel anticholinergic agent | |
| WO2017146994A1 (en) | Controlled agglomeration of micronized drug or drug-excipient mixtures | |
| CA1144862A (en) | Composition | |
| Rajalingam | A DEVELOPMENT AND COMPREHENSIVE ASSESSMENT OF ENTERIC–COATED PELLETS | |
| GB1569612A (en) | Disodium cromoglycate pellets or granules | |
| IE45261B1 (en) | Disodium cromoglycate pellets or granules | |
| LI | Studies on spheronization processes by rotary and extrusion | |
| POWDERS | SOLID DOSAGE FORMS: POWDERS AND GRANULES | |
| Summers | CHAPTER CONTENTS Introduction..... 466 Reasons for granulation.. 466 Powdered and granulated products as dosage forms..... 467 |